{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:15:42Z","timestamp":1761387342557,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bbalip.2021.159031","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T02:08:42Z","timestamp":1629511722000},"page":"159031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vasodilation and blood pressure-lowering effect mediated by 5,6-EEQ lactone in 5\/6 nephrectomy hypertensive rats"],"prefix":"10.1016","volume":"1866","author":[{"given":"Michal","family":"Barsheshet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Offir","family":"Ertracht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Boginya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Reuveni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaul","family":"Atar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Szuchman-Sapir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbalip.2021.159031_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"10.1016\/j.bbalip.2021.159031_bb0010","first-page":"509","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.bbalip.2021.159031_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1152\/physiol.00026.2016","article-title":"The hypertension pandemic: an evolutionary perspective","volume":"32","author":"Rossier","year":"2017","journal-title":"Physiology."},{"issue":"6","key":"10.1016\/j.bbalip.2021.159031_bb0020","first-page":"e116","article-title":"Systematic review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology\/American Heart Association","volume":"71","author":"Reboussin","year":"2018","journal-title":"Hypertens (Dallas, Tex 1979)."},{"key":"10.1016\/j.bbalip.2021.159031_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/5584_2016_90","article-title":"Endothelial dysfunction and hypertension","volume":"6","author":"Konukoglu","year":"2016","journal-title":"Advs Exp. Medicine, Biology-Neuroscience and Respiration."},{"issue":"14","key":"10.1016\/j.bbalip.2021.159031_bb0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1089\/ars.2014.6150","article-title":"Whatever happened to the epoxyeicosatrienoic acid-like endothelium-derived hyperpolarizing factor? The identification of novel classes of lipid mediators and their role in vascular homeostasis","volume":"22","author":"Fr\u00f6mel","year":"2015","journal-title":"Antioxid. Redox Signal."},{"issue":"2017","key":"10.1016\/j.bbalip.2021.159031_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.05.005","article-title":"Cytochrome P450-derived eicosanoids and heart function","volume":"179","author":"Jamieson","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbalip.2021.159031_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106407","article-title":"Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome","volume":"148","author":"dos Santos","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"5","key":"10.1016\/j.bbalip.2021.159031_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.33549\/physiolres.934291","article-title":"Epoxyeicosanoids in hypertension","volume":"68","author":"Imig","year":"2019","journal-title":"Physiol. Res."},{"issue":"7","key":"10.1016\/j.bbalip.2021.159031_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1358\/dof.2009.34.7.1391872","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"34","author":"Fang","year":"2009","journal-title":"Drugs Future"},{"issue":"4","key":"10.1016\/j.bbalip.2021.159031_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FJC.0000000000000523","article-title":"Orally active epoxyeicosatrienoic acid analogs","volume":"70","author":"Campbell","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbalip.2021.159031_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-26325-4","article-title":"Comprehensive analysis of the mouse cytochrome P450 family responsible for omega-3 epoxidation of eicosapentaenoic acid","volume":"8","author":"Isobe","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2021.159031_bb0065","first-page":"143","article-title":"Emerging class of omega-3 fatty acid endocannabinoids & their derivatives","author":"Watson","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bbalip.2021.159031_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.016","article-title":"Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases","volume":"183","author":"Schunck","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bbalip.2021.159031_bb0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1165\/rcmb.2009-0155OC","article-title":"17,18-epoxyeicosatetraenoic acid targets PPAR\u03b3 and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung role of soluble epoxide hydrolase","volume":"43","author":"Morin","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.bbalip.2021.159031_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.taap.2012.09.007","article-title":"Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids","volume":"264","author":"Agbor","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"43","key":"10.1016\/j.bbalip.2021.159031_bb0085","doi-asserted-by":"crossref","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","article-title":"Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of \u03c9-3 fatty acids","volume":"285","author":"Arnold","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bbalip.2021.159031_bb0090","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1021\/jm200132q","article-title":"17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues","volume":"54","author":"Falck","year":"2011","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbalip.2021.159031_bb0095","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1113\/expphysiol.2007.038166","article-title":"The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK \u03b1 channel subunit in rodents","volume":"92","author":"Hercule","year":"2007","journal-title":"Exp. Physiol."},{"issue":"1","key":"10.1016\/j.bbalip.2021.159031_bb0100","article-title":"Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung","volume":"296","author":"Morin","year":"2009","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"1","key":"10.1016\/j.bbalip.2021.159031_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbalip.2021.159031_bb0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvq411","article-title":"Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity","volume":"90","author":"Wang","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"6 49-6","key":"10.1016\/j.bbalip.2021.159031_bb0115","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1152\/ajpheart.2001.280.6.H2430","article-title":"EET homologs potently dilate coronary microvessels and activate BKCa channels","volume":"280","author":"Zhang","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2 II","key":"10.1016\/j.bbalip.2021.159031_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/hy0202.103293","article-title":"Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators","volume":"39","author":"Lauterbach","year":"2002","journal-title":"Hypertension."},{"issue":"2","key":"10.1016\/j.bbalip.2021.159031_bb0125","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/jpet.303.2.768","article-title":"Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels","volume":"303","author":"Ye","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bbalip.2021.159031_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apha.13297","article-title":"A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury","volume":"227","author":"Hoff","year":"2019","journal-title":"Acta Physiol."},{"key":"10.1016\/j.bbalip.2021.159031_bb0135","series-title":"Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function","volume":"77","author":"Imig","year":"2016"},{"issue":"December 2016","key":"10.1016\/j.bbalip.2021.159031_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.freeradbiomed.2016.12.022","article-title":"5,6-\u03b4-DHTL, a stable metabolite of arachidonic acid, is a potential EDHF that mediates microvascular dilation","volume":"103","author":"Levi-Rosenzvig","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"9","key":"10.1016\/j.bbalip.2021.159031_bb0145","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.bbalip.2015.04.008","article-title":"5,6-\u03b4-DHTL, a stable metabolite of arachidonic acid, is a potential substrate for paraoxonase 1","volume":"1851","author":"Eryanni-Levin","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"3","key":"10.1016\/j.bbalip.2021.159031_bb0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbalip.2018.12.008","article-title":"Paraoxonase 1 in endothelial cells impairs vasodilation induced by arachidonic acid lactone metabolite","volume":"1864","author":"Gilad","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"7","key":"10.1016\/j.bbalip.2021.159031_bb0155","first-page":"1","article-title":"High fibroblast growth factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes","volume":"6","author":"Verkaik","year":"2018","journal-title":"Phys. Rep."},{"issue":"3","key":"10.1016\/j.bbalip.2021.159031_bb0160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/HYPERTENSIONAHA.114.03585","article-title":"Epoxyeicosatrienoic acids, hypertension, and kidney injury","volume":"65","author":"Imig","year":"2015","journal-title":"Hypertension."},{"issue":"3","key":"10.1016\/j.bbalip.2021.159031_bb0165","article-title":"Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease","volume":"302","author":"Elmarakby","year":"2012","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"5","key":"10.1016\/j.bbalip.2021.159031_bb0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.amjms.2016.02.030","article-title":"Interlobular arteries from 2-kidney, 1-clip goldblatt hypertensive rats\u2019 exhibit-im paired vasodilator response to epoxyeicosatr ienoic acids","volume":"351","author":"Sporkov\u00e1","year":"2016","journal-title":"Am J Med Sci"},{"issue":"12","key":"10.1016\/j.bbalip.2021.159031_bb0175","article-title":"Novel CYP-eicosanoid derivatives","volume":"450","author":"Schunck","year":"2014"},{"issue":"7","key":"10.1016\/j.bbalip.2021.159031_bb0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/CS20130479","article-title":"Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition","volume":"127","author":"Gauthier","year":"2014","journal-title":"Clin. Sci."},{"key":"10.1016\/j.bbalip.2021.159031_bb0185","article-title":"Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats","volume":"34","author":"J\u00edchov\u00e1","year":"2016"},{"issue":"6","key":"10.1016\/j.bbalip.2021.159031_bb0190","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HJH.0000000000001708","article-title":"Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension","volume":"36","author":"\u010cervenka","year":"2018","journal-title":"J. Hypertens."},{"issue":"SEP","key":"10.1016\/j.bbalip.2021.159031_bb0195","first-page":"1","article-title":"Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury","volume":"5","author":"Khan","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbalip.2021.159031_bb0200","doi-asserted-by":"crossref","unstructured":"Imig JD, Elmarakby A, Nithipatikom K, et al. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front. Physiol. 2010;1 DEC(December):1\u20138. doi:https:\/\/doi.org\/10.3389\/fphys.2010.00157.","DOI":"10.3389\/fphys.2010.00157"},{"issue":"3","key":"10.1016\/j.bbalip.2021.159031_bb0205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.mnh.0000222691.53970.83","article-title":"Progression of chronic kidney disease: insights from animal models","volume":"15","author":"Zoja","year":"2006","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"7","key":"10.1016\/j.bbalip.2021.159031_bb0210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/CS20120074","article-title":"Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications","volume":"123","author":"Briet","year":"2012","journal-title":"Clin. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198121001591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198121001591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:12:13Z","timestamp":1761387133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198121001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1388198121001591"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2021.159031","relation":{},"ISSN":["1388-1981"],"issn-type":[{"type":"print","value":"1388-1981"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasodilation and blood pressure-lowering effect mediated by 5,6-EEQ lactone in 5\/6 nephrectomy hypertensive rats","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2021.159031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"159031"}}